Papers

3

Total Citations

36

H-Index

3

About

Daniel Buergy is a leading radiation oncologist whose research focuses on stereotactic body radiotherapy (SBRT) for liver metastases and the emerging field of cardiac radioablation. His major contribution lies in demonstrating that active motion-compensation during liver SBRT achieves excellent local control for oligometastatic disease, as shown in his highly cited 2021 pooled multi-platform cohort analysis (21 citations). This work established a benchmark for treating liver tumors with precision. Buergy also played a pivotal role in the RAdiosurgery for VENtricular TAchycardia (RAVENTA) trial, where he led a multicenter, multiplatform benchmarking study for treatment planning in cardiac radioablation (12 citations). His 2023 long-term MRI analysis further characterized normal tissue changes after liver SBRT, providing critical insights for multimodal treatment planning. Through these contributions, Buergy has advanced both liver SBRT and cardiac radioablation, demonstrating the power of motion management and collaborative trial design to improve patient outcomes.

Research Focus

Key Achievements

3
H-Index
3
Papers
36
Total Citations
12
Avg Citations/Paper
🏆 Most Cited Paper
Liver SBRT with active motion-compensation results in excellent local control for liver oligometastases: An outcome analysis of a pooled multi-platform patient cohort
21 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 40
🏛 Institutions: University Medical Centre Mannheim, University Hospital Heidelberg

Top Papers

  1. 1
  2. 2
  3. 3

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago